logo
More than two thirds of cancer patients waiting over TWO MONTHS to start treatment in parts of England - how does YOUR area fare?

More than two thirds of cancer patients waiting over TWO MONTHS to start treatment in parts of England - how does YOUR area fare?

Daily Mail​6 hours ago

England's 'deadly' cancer treatment postcode lottery was today laid bare in a damning analysis revealing where patients are having to wait months for care.
More than two thirds (69 per cent) of patients at Royal Papworth Hospital NHS Foundation Trust in Cambridgeshire had to wait over 62 days to start treatment for their disease after an urgent referral from their GP in April.
This was more than double the proportion waiting too long for cancer treatment nationally.
By comparison, NHS guidelines state that 85 per cent of patients should start treatments like surgery, chemotherapy and radiotherapy, within two months.
Senior cancer doctors said the data highlights the 'frightening truth' that too many patients were experiencing fatal delays.
Prompt treatment for cancer is considered critical, with every four weeks a patient is forced to wait, linked to a 10 per cent increase chance of death.
Mid and South Essex NHS Foundation Trust ranked second worst in the nation for speedy cancer treatment, with more than half (55 per cent) of patients having to wait at least two months.
Liverpool Women's NHS Foundation Trust followed, at 51 per cent of patients and Northern Lincolnshire and Goole NHS Foundation Trust with 48 per cent of patients waiting too long.
Joint fifth were Hull University Teaching Hospitals NHS Trust, The Princess Alexandra Hospital NHS Trust in Essex, University Hospitals Birmingham NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust and Sheffield Teaching Hospitals NHS Foundation Trust.
A total of 47 per cent of cancer patients referred by their family doctor for signs of the disease had to wait too long to start treatment at these trusts.
Nationally, around one in three cancer patients (30.1 per cent), over 8,000 people, had to wait over two months to start treatment.
Reacting to the data top oncologist and co-founder of the Catch Up With Cancer campaign, Professor Pat Price, said: 'This data shows the frightening truth that a third of patients following an urgent GP cancer referral do not get their treatment on time.
'These deadly delays show that the Government needs to urgently invest in cancer treatments.'
She added: 'It is still the case that there is a deadly postcode lottery when it comes to cancer treatments.
'For instance, in radiotherapy, despite some investment last year, around half of the cancer treatment machines for radiotherapy are spiralling towards their expiration date.'
Despite the NHS target of 85 per cent, this goal hasn't been met since 2015.
Rapid access to cancer treatment can boost patient survival as it reduces the chances of a tumour growing larger—which requires more extensive treatment— or the disease spreading to other parts of the body, a far more serious stage.
At the opposite end of the scale, Liverpool Heart and Chest Hospital NHS Foundation Trust recorded the highest adherence to the target with 96 per cent of cancer patients starting treatment within two months.
This was followed by Moorfields Eye Hospital NHS Foundation Trust which saw 92 per cent of cancer patients within the 62-day target.
Both trusts are specialty hospitals meaning they will generally see fewer cancer patients than a normal NHS trust.
The analysis was carried out by medical negligence law firm Patient Claim Line.
The firm's senior litigation executive Michael Blakemore-Carson suggested delays could be devastating to patients and potentially costly to the NHS.
'If you have experienced delayed treatment, you could be entitled to make a claim for compensation,' he said.
A Royal Papworth Hospital NHS Foundation Trust spokesperson said: We are sorry that too many cancer patients are waiting longer than they should.
'We are working collaboratively internally and with our partner hospitals to make sure referrals reach us earlier, so we can provide the very best, timely care.'
A spokesperson for NHS Humber Health Partnerships, which represents Northern Lincolnshire and Goole NHS Foundation Trust and Hull University Teaching Hospitals NHS Trust, blamed the figures on rising cancer cases in the area.
'We are working hard to minimise delays to our patients who are waiting to start their cancer treatment, and I am sorry some people are waiting longer than we would like,' they said.
'However, we are seeing a striking growth in the number of referrals coming into our hospitals. To try to deal with this we are providing additional "one stop" sessions at weekends, thanks to the help of our medical, nursing and imaging staff.'
Stephanie Lawton, chief operating officer at The Princess Alexandra Hospital NHS Trust also said the trust was working to reduce waiting times for cancer patients.
'We are focusing on initiatives including additional clinical triage of all patient referrals, further diagnostic and outpatient capacity, and a review of our external pathways to support patients requiring onward referral to specialist centres,' she said.
'In some services, we are working on "one-stop" diagnostic capacity, so patients have all their investigations in one visit.'
Christine Blanshard, chief medical Officer for Mid and South Essex NHS Foundation Trust, also said they were working to make improvements.
'Our priority is to provide the highest possible quality of patient care, and we appreciate how difficult it is for anyone waiting for cancer treatment,' she said.
'We are implementing an improvement plan focused on rapidly reducing cancer diagnosis and treatments times.'
Kirsten Major, Chief Executive, Sheffield Teaching Hospitals NHS Foundation Trust said: Reducing the time patients wait for cancer treatment is a top priority and whilst we have more work to do, we have already reduced the wait time by five days following focused work to increase both staffing and capacity over the past year.'
Other NHS data shows other cancer targets are struggling to meet ministers' ambitions.
The Government has target that by March 2026, 80 per cent of all urgent cancer referrals should be either diagnosed or ruled out within 28 days.
But the latest figures show this was only true for 76.7 per cent of patients in April, down from 78.9 per cent in March.
Both figures are above the current target of 75 per cent of patients being told they have disease or have it ruled out within this time frame.
Another target, that cancer patients should only wait a month from a decision to treat their cancer to starting that treatment was also missed.
The NHS only managed to treat 91.3 per cent of cancer patients within 31 days. The target is 96 per cent.
Oncologists—doctors who specialise in cancer care—have previously described the continuing failure for the NHS to meet its cancer treatment targets as a 'heartbreaking disaster'.
Almost 400,000 cancer cases are diagnosed across the UK each year, with almost 170,000 deaths from the disease recorded per annum.
Nearly half of all Britons—45 per cent of men and 43 per cent of women—are expected to be diagnosed with some form of cancer during their lifetime.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

25 UK holidaymakers fell ill on 'nightmare' five-star holiday
25 UK holidaymakers fell ill on 'nightmare' five-star holiday

Wales Online

time9 minutes ago

  • Wales Online

25 UK holidaymakers fell ill on 'nightmare' five-star holiday

25 UK holidaymakers fell ill on 'nightmare' five-star holiday They have reported dirty plates, flies and raw food before dozens fell ill Holidaymakers say some of the food was not cooked properly A group of 25 British tourists are seeking legal action after falling seriously ill on "nightmare" holidays to a luxury five-star resort in Cape Verde. Hotel guests said their dream trips quickly turned into holidays from hell after they suffered gastric illnesses while staying in Boa Vista. Holidaymakers reported seeing birds, flies and even cats around the buffet area, which also served "raw and undercooked" food along with "dirty crockery and cutlery." One NHS worker who spent £3,000 on a trip to celebrate early retirement was left hospitalised after being stuck down with ‌ Sharon Burrow said she still suffers from complications eight months on after the luxury break turned into "one of the worst experiences of her life". Another guest, Penny Robson had to be given antibiotics after coming down with gastric symptoms including bloating, diarrhoea, nausea and stomach cramping. ‌ Sharon Burrows The pair are among 25 people who have now instructed lawyers to investigate after raising concerns about hygiene standards at the resort. Sharon, 56, of Ashton-under-Lyne, Greater Manchester, travelled to Cape Verde for a ten day break on September 20, 2024. But around five days into the holiday, she started to suffer from aches and pains, and a fever before experiencing stomach cramps and diarrhoea. Sharon visited A&E upon her return to the UK and tests confirmed she had and shigella. She said doctors suspected she contracted the infection on holiday. Article continues below The mental health worker said: 'I was unwell for nearly three weeks and it was one of the worst experiences of my life. 'I was in so much pain and completely drained - it felt like my body just shut down. I'd been concerned about hygiene at the hotel. Food was served at room temperature and new food was added to existing food. "I saw dirty crockery, cats in and around the restaurant and empty plates attracting flies were left on tables. I feel completely let down and while it's too late for me the least I feel I deserve is answers and to raise awareness of what I've been through so hopefully others don't have to.' Penny, a 55-year-old paramedic from London, travelled to the resort in September 2023 and paid £2,000 for the week-long break with her friend. She was left requiring medical treatment at the resort, including antibiotics and electrolytes, after she fell poorly five days into the holiday. ‌ Penny Robson Penny had to cancel two pre-paid excursions, including a stargazing trip and a private island tour. She raised concerns about the food hygiene at the resort, reporting that food was often served lukewarm, left uncovered, and exposed to birds and flies. On one occasion, she picked up a piece of chicken from the buffet and discovered it was raw. Since returning home, Penny says she has experienced ongoing anxiety and the illness has had a lasting impact on her confidence and wellbeing. ‌ Penny said: 'I was looking forward to my holiday and had saved for months. However, the excitement for the holiday quickly disappeared when I started feeling unwell. It completely ruined what should have been a relaxing time. I've never felt so vulnerable while abroad. 'I'm very cautious now regarding where I would book a holiday. This has affected my choices and I travel much shorter distances to Europe as I don't feel confident travelling to further afield places. 'I no longer trust my body and if I ever eat out I constantly worry about food and how it's prepared. I just want answers as to how my holiday became a nightmare.' ‌ Law firm Irwin Mitchell is currently representing more than 1,400 holidaymakers who suffered serious illnesses linked to holidays in Cape Verde since 2022. Jatinder Paul, the international serious injury lawyer representing those who have fallen ill, said: 'This is yet another resort in Cape Verde that has come under the spotlight following reports of serious illness. 'We're already representing more than 1,400 British holidaymakers who have suffered gastric illness linked to holidays on the islands over the last three years. Illnesses like are serious and can lead to long-term health complications. It's vital that if any issue are identified, swift action is taken to eradicate the risks to other holidaymakers. 'While nothing can make up for their ordeals, this latest group we represent understandably want answers. They booked what they hoped would be luxury holidays, but the first-hand accounts we've heard about their holiday were anything but luxury. Article continues below 'As part of our investigations, we would be interested in hearing from other guests staying at the hotel at the same time as this group.' The resort has been contacted for comment.

Weight loss jabs like Mounjaro now linked to more than a HUNDRED deaths, the UK's drug watchdog confirms
Weight loss jabs like Mounjaro now linked to more than a HUNDRED deaths, the UK's drug watchdog confirms

Daily Mail​

time17 minutes ago

  • Daily Mail​

Weight loss jabs like Mounjaro now linked to more than a HUNDRED deaths, the UK's drug watchdog confirms

Slimming jabs like Mounjaro and Wegovy have been linked to more than 100 deaths in Britain, it was revealed today. None of the fatalities, which have all been reported since the jabs were licensed for use in the UK, are proven to have been caused directly by the drugs. However, health chiefs tasked with policing the safety of medicines admit reports of side effects indicate 'a suspicion' they may have been to blame. A total of 111 deaths were logged with the regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), up to and including May 29. These are based on patients' families or healthcare workers informing the MHRA of a suspected fatal reaction to the drugs, known as glucagon-like peptide-1 receptor agonists (GLP-1RAs). It comes just months after the death Scottish nurse Susan McGowan, 58, who experienced multiple organ failure, septic shock and pancreatitis after taking just two doses of Mounjaro. Hers is the only confirmed fatality linked to the jabs in the UK. But it comes at a time when ministers are planning to rollout the jabs—described as game changers in the fight against obesity— to even more Britons. The deaths may also be caused by underlying medical conditions or other medications taken at the same time and therefore can be coincidental the MHRA told trade magazine Chemist+Druggist. Officials use the MHRA's 'Yellow Card' database, set-up in the wake of the 1960s thalidomide scandal, to track the safety of medications currently in use in Britain. Although almost impossible to prove, the system allows doctors, pharmacists and patients to report adverse reactions they believe are linked to medications and allows officials to uncover potential patterns. The weight-loss medication linked to the most deaths, in the system was liraglutide—sold under the brand name Saxenda—with 37 reports of a fatal outcome. In second place was tirzepatide—sold as Mounjaro and once hailed the 'King Kong' of slimming jabs—with 33 deaths. And in third place was semaglutide—the active ingredient in the weight loss jab Wegovy as well diabetes drug Ozempic—which was linked to 30 deaths. A further seven reports were liked to dulaglutide—known as Trulicity—and five to lixisenatide—which has the trade name Lyxumia. Of the total fatal reports, 32 involved jabs indicated for 'weight management alone or 'only licensed for weight management—Mounjaro, Saxenda, Wegovy'. Meanwhile, 40 reports related to drugs with an indication for 'diabetes alone'. Another nine referred to patients getting the jab for 'both weight management or diabetes'. While 30 reported a fatal outcome 'with an indication other than weight management or diabetes, or where no indication has been reported', the watchdog told Chemist+Druggist. Last year, medics warned they were seeing a wave of patients of healthy weight taking the drugs in a bid to become 'beach-body ready'. Such patients, mostly young women, were landing in A&E after obtaining the drugs online under false pretences. Currently, patients can obtain the drugs from many chemists by filling in online forms with details of their weight and height and submitting photographs of themselves. However, experts and organisations such as the Society for Acute Medicine have called for tighter restrictions on how Ozempic, Mounjaro and other weight-loss products are prescribed. A spokesperson for Lilly UK, the makers of Mounjaro, said patient safety is its 'top priority'. It added: 'Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine and Lilly is committed to continually monitoring, evaluating, and reporting safety data.' 'If anyone is experiencing side effects when taking any Lilly medicine, they should talk to their doctor or other healthcare professional.' There has been growing concern after reports of side effects from the drugs. These include including nausea, vomiting, diarrhoea, bone fractures, tooth damage, severe anxiety and depression. Earlier this month, women reported terrifying mental health side effects after using Mounjaro. The jab, along with similar treatments such as Ozempic and Wegovy, can help patients lose up to 15 per cent of their body weight in a year.

Genetic testing study 'could help personalise treatments for patients'
Genetic testing study 'could help personalise treatments for patients'

STV News

time27 minutes ago

  • STV News

Genetic testing study 'could help personalise treatments for patients'

A new study aims to show how genetic testing could help personalise treatments by boosting medication response and reducing harmful side effects. The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications. It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time. Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change. Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care. Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up. Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects. In some cases, the prescribed drug may be ineffective, or a different dosage may be needed. The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit. Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers. It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience. Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery. He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times. Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it. 'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.' Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. 'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. 'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures. 'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.' Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. 'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. 'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.' Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare. 'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. 'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store